NRX Pharmaceuticals (NRXP) Receivables (2020 - 2026)

NRX Pharmaceuticals (NRXP) has 6 years of Receivables data on file, last reported at $362000.0 in Q1 2026.

• On a quarterly basis, Receivables changed N/A year-over-year to $362000.0 in Q1 2026; TTM through Mar 2026 was $362000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $161000.0, changed N/A from the prior year.
• Receivables for Q1 2026 stood at $362000.0, up from $161000.0 in the prior quarter.
• Over the last five years, Receivables for NRXP reached as high as $3.3 million in Q3 2025 and fell as low as $6000.0 in Q1 2023.
• Historically, Receivables has averaged $461666.7 across 5 years, with a median of $12000.0 in 2023.
• Across the five-year window, Receivables sank 95.56% in 2023 and changed 0.0% in 2024, its largest moves.
• Year by year, Receivables stood at $270000.0 in 2022, then sank by 95.56% to $12000.0 in 2023, then slumped by 50.0% to $6000.0 in 2024, then surged by 2583.33% to $161000.0 in 2025, then soared by 124.84% to $362000.0 in 2026.
• Per Business Quant data, the three most recent Receivables figures were $362000.0 in Q1 2026, $161000.0 in Q4 2025, and $3.3 million in Q3 2025.